Metals in Imaging of Alzheimer’s Disease

Metals in Imaging of Alzheimer’s Disease

One of the hallmarks of Alzheimer’s disease (AD) is the deposition of amyloid plaques in the brain parenchyma, which occurs 7–15 years before the onset of cognitive symptoms of the pathology. Timely diagnostics of amyloid formations allows identifying AD at an early stage and initiating inhibitor th...

Full description

Bibliographic Details
Main Authors:	Olga Krasnovskaya, Daniil Spector, Alexander Zlobin, Kirill Pavlov, Peter Gorelkin, Alexander Erofeev, Elena Beloglazkina, Alexander Majouga
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	International Journal of Molecular Sciences
Subjects:	Alzheimer disease amyloid PET SPECT MRI
Online Access:	https://www.mdpi.com/1422-0067/21/23/9190

Similar Items

Aβ-Targeting Bifunctional Chelators (BFCs) for Potential Therapeutic and PET Imaging Applications
by: Olga Krasnovskaya, et al.
Published: (2022-12-01)

Tacrine-Based Hybrids: Past, Present, and Future
by: Anna Bubley, et al.
Published: (2023-01-01)

Recent Advances in <sup>64</sup>Cu/<sup>67</sup>Cu-Based Radiopharmaceuticals
by: Olga O. Krasnovskaya, et al.
Published: (2023-05-01)

Copper Coordination Compounds as Biologically Active Agents
by: Olga Krasnovskaya, et al.
Published: (2020-05-01)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
by: Daniil Spector, et al.
Published: (2021-04-01)

Posterior cortical atrophy: A rare variant of Alzheimer’s disease
by: Michael A. Meyer, et al.
Published: (2018-05-01)

Support vector machine-based classification of neuroimages in Alzheimer’s disease: direct comparison of FDG-PET, rCBF-SPECT and MRI data acquired from the same individuals
by: Luiz K. Ferreira, et al.
Published: (2017-10-01)

Electroencephalography-driven approach to prodromal Alzheimer's disease diagnosis: from biomarker integration to network-level comprehension
by: Moretti DV
Published: (2016-07-01)

Drug development in Alzheimer’s disease: the contribution of PET and SPECT
by: Lieven Denis Herwig Declercq, et al.
Published: (2016-03-01)

Evaluating [68Ga]Ga-p14-032 as a Novel PET Tracer for Diagnosis Cerebral Amyloid Angiopathy
by: Qihui Zhang, et al.
Published: (2021-10-01)

Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease
by: Leon Stefanovski, et al.
Published: (2019-08-01)

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls
by: Poul F. Høilund-Carlsen, et al.
Published: (2023-07-01)

Alzheimer's disease heterogeneity revealed by neuroanatomical normative modeling
by: Flavia Loreto, et al.
Published: (2024-01-01)

Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
by: Daniil Spector, et al.
Published: (2022-11-01)

Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study
by: Paul Edison, et al.
Published: (2008-12-01)

Design, Synthesis and Molecular Modeling Study of Radiotracers Based on Tacrine and Its Derivatives for Study on Alzheimer’s Disease and Its Early Diagnosis
by: Przemysław Koźmiński, et al.
Published: (2024-03-01)

What Has Neuroimaging Taught Us on the Neurobiology of Yoga? A Review
by: June van Aalst, et al.
Published: (2020-07-01)

18F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer’s Disease Patients
by: Yan Chang, et al.
Published: (2020-07-01)

Diagnostic biomarkers in Alzheimer’s disease
by: Emerlee Andersen, et al.
Published: (2021-12-01)

Editorial: Status Go for Preclinical Imaging
by: Claudia Kuntner, et al.
Published: (2020-09-01)

Editorial: Radiopharmaceuticals, Imaging Techniques and Clinical Applications in Neurodegenerative Diseases
by: Chuantao Zuo, et al.
Published: (2019-09-01)

Imaging modalities in differential diagnosis of Parkinson’s disease: opportunities and challenges
by: Tohid Mortezazadeh, et al.
Published: (2021-03-01)

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
by: Azadeh Firouzian, et al.
Published: (2018-03-01)

Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer’s Disease
by: Helena Colvee-Martin, et al.
Published: (2024-03-01)

Imaging the Limbic System in Parkinson’s Disease—A Review of Limbic Pathology and Clinical Symptoms
by: Magdalena Banwinkler, et al.
Published: (2022-09-01)

Biomarker selection and imaging design in cancer: A link with biochemical pathways for imminent engineering
by: Joham Surfraz Ali, et al.
Published: (2020-02-01)

Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?
by: Rodolfo Ferrando, et al.
Published: (2021-05-01)

Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers
by: Petrice M. Cogswell, et al.
Published: (2021-01-01)

Implication of tau propagation on neurodegeneration in Alzheimer’s disease
by: Daniel Lamontagne-Kam, et al.
Published: (2023-07-01)

In vivo Imaging With 18F-FDG- and 18F-Florbetaben-PET/MRI Detects Pathological Changes in the Brain of the Commonly Used 5XFAD Mouse Model of Alzheimer's Disease
by: Timon N. Franke, et al.
Published: (2020-09-01)

11C-PIB PET imaging reveals that amyloid deposition in cases with early-onset Alzheimer’s disease in the absence of known mutations retains higher levels of PIB in the basal ganglia
by: Youn YC, et al.
Published: (2017-06-01)

Time between milestone events in the Alzheimer's disease amyloid cascade
by: Philip S. Insel, et al.
Published: (2021-02-01)

Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer’s Disease with APP Osaka Mutation
by: Hiroyuki Shimada, et al.
Published: (2020-06-01)

The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study
by: Rola Ismail, et al.
Published: (2020-05-01)

PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome
by: Matthew D. Zammit, et al.
Published: (2021-03-01)

The Roles of Imaging Biomarkers in the Management of Chronic Neuropathic Pain
by: Cosmin Vasilica Pricope, et al.
Published: (2022-10-01)

Lack of association between acute stroke, post-stroke dementia, race, and β-amyloid status
by: Lauren N. Koenig, et al.
Published: (2021-01-01)

Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study
by: Julien Lagarde, et al.
Published: (2023-05-01)

The Down Syndrome Biomarker Initiative (DSBI) Pilot: Proof of Concept for Deep Phenotyping of Alzheimer’s Disease Biomarkers in Down Syndrome
by: Michael eRafii, et al.
Published: (2015-09-01)

Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
by: Giulia Giacomucci, et al.
Published: (2021-01-01)